ArticleFrontiers in genetics2020
Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Pooled it
- Trial
- Clinical utility of OGN in pan-cancer: diagnostic biomarker and immune microenvironment regulator.Translational cancer research · 2026Article
- Visual analytics framework for survival analysis and biomarker discovery from gene expression data.PloS one · 2026Article
- A signature constructed with circadian rhythm-related genes to predict the prognosis and therapy response for low-grade gliomas.Discover oncology · 2025Article
- Identifying survival subtypes with autoencoder using multiple types of high-dimensional genomic data from studies of glioblastoma multiforme.Briefings in bioinformatics · 2025Article
- Explainable Machine Learning Models for Glioma Subtype Classification and Survival Prediction.Cancers · 2025Article
- A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness.Scientific reports · 2025Article
- Multicellular Network-Informed Survival Model for Identification of Drug Targets of Gliomas.IEEE journal of biomedical and health informatics · 2025Article
- Article
- Article
- The dual role of calnexin on malignant progression and tumor microenvironment in glioma.Scientific reports · 2024Article
- Necroptosis-based glioblastoma prognostic subtypes: implications for TME remodeling and therapy response.Annals of medicine · 2024Article
- TMEM35B as a novel biomarker for diagnosing gliomas.Biomarkers in medicine · 2024Article
- Decoding the immune microenvironment: unveiling CD8 + T cell-related biomarkers and developing a prognostic signature for personalized glioma treatment.Cancer cell international · 2024Article
- Article
- Hypoxia-related THBDJournal of cellular and molecular medicine · 2024Article
- Construction of a New Immune-Related Competing Endogenous RNA Network with Prognostic Value in Lung Adenocarcinoma.Molecular biotechnology · 2024Article
- Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.European journal of medical research · 2024Article
- IGFBP5, as a Prognostic Indicator Promotes Tumor Progression and Correlates with Immune Microenvironment in Glioma.Journal of Cancer · 2024Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDespite several clinicopathological factors being integrated as prognostic biomarkers, the individual variants and risk stratification have not been fully elucidated in lower grade glioma (LGG). With the prevalence of gene expression profiling in LGG, and based on the critical role of the immune microenvironment, the aim of our study was to develop an immune-related signature for risk stratification and prognosis prediction in LGG.
methodsRNA-sequencing data from The Cancer Genome Atlas (TCGA), Genome Tissue Expression (GTEx), and Chinese Glioma Genome Atlas (CGGA) were used. Immune-related genes were obtained from the Immunology Database and Analysis Portal (ImmPort). Univariate, multivariate cox regression, and Lasso regression were employed to identify differentially expressed immune-related genes (DEGs) and establish the signature. A nomogram was constructed, and its performance was evaluated by Harrell's concordance index (C-index), receiver operating characteristic (ROC), and calibration curves. Relationships between the risk score and tumor-infiltrating immune cell abundances were evaluated using CIBERSORTx and TIMER.
resultsNoted, 277 immune-related DEGs were identified. Consecutively, 6 immune genes (
conclusionThe present study constructed a robust six immune-related gene signature and established a prognostic nomogram effective in risk stratification and prediction of overall survival in primary LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.